AVH.AX
AVITA Medical, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 1,
"returned": 1,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "3b4fb3cf-a542-48e2-9880-0ed689112d36",
"title": "AVITA Medical Reports First Quarter Financial Results",
"description": "AVITA Medical (NASDAQ: RCEL, ASX: AVH) today reported financial results for the first quarter ended March 31, 2024....",
"keywords": "Australian Stock Exchange:AVH.AX, AVITA Medical, avita earnings, avita medical results, avita first quarter",
"snippet": "VALENCIA, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on fir...",
"url": "https://www.globenewswire.com/news-release/2024/05/13/2880848/0/en/AVITA-Medical-Reports-First-Quarter-Financial-Results.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/53ad8139-952a-4470-9ede-2f3bf0521f16",
"language": "en",
"published_at": "2024-05-13T20:01:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "AVH.AX",
"name": "AVITA Medical, Inc.",
"exchange": null,
"exchange_long": null,
"country": "au",
"type": "equity",
"industry": "Healthcare",
"match_score": 107.823875,
"sentiment_score": 0.415645,
"highlights": [
{
"highlight": "., May 13, 2024 (GLOBE NEWSWIRE) -- <em>AVITA</em> <em>Medical</em>, <em>Inc</em>. (NASDAQ: RCEL, <em>ASX</em>: <em>AVH</em>), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the first quarter ended March 31, 2024.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "to $11.1 million compared to the same period in 2023\n\nGross profit margin of 86.4%\n\nLaunched PermeaDerm, a co-branded biosynthetic wound matrix, in the U.S. on March 23, 2024\n\n“We believe we have taken the necessary measures to invigorate our burns business and improve our commercial sales process to return to sustained growth,\" said Jim Corbett, <em>AVITA</em>",
"sentiment": 0.7269,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medical</em> Chief Executive Officer.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Simultaneously, we are actively transforming <em>AVITA</em> <em>Medical</em> into a broad wound care business by expanding our portfolio to address the full spectrum of clinical needs. We are confident that our strategic initiatives to transform our business will enhance accessibility and reach more patients.\"",
"sentiment": 0.8316,
"highlighted_in": "main_text"
},
{
"highlight": "Expect to achieve previously given guidance of cashflow break even and GAAP profitability no later than the third quarter of 2025\n\n\"We acknowledge the significant cash utilization this quarter, however we remain confident in our financial stability and our ability to reach cashflow break even as guided,\" said David O'Toole, Chief Financial Officer of <em>AVITA</em>",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medical</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Webcast and Conference Call Information\n\n<em>AVITA</em> <em>Medical</em> will host a conference call to discuss its financial and business results on Monday, May 13, 2024, at 1:30 p.m. Pacific Time (being Tuesday, May 14, 2024, at 6:30 a.m. Australian Eastern Standard Time).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>AVITA</em> <em>Medical</em>, <em>Inc</em>.\n\n<em>AVITA</em> <em>Medical</em>® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices.",
"sentiment": 0.8519,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AVITA</em> <em>Medical</em> also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, in the United States.\n\nIn international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "Authorized for release by the Chief Financial Officer of <em>AVITA</em> <em>Medical</em>, <em>Inc</em>.\n\n<em>AVITA</em> <em>MEDICAL</em>, <em>INC</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AVITA</em> <em>Medical</em> Reports First Quarter Financial Results",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "AVH.AX",
"total_documents": 1,
"sentiment_avg": 0.4156450033187866
}
]
}
Other details
Exchange
- Australian Securities Exchange
- equity
- Healthcare
- au